z-logo
open-access-imgOpen Access
Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents
Author(s) -
Gregg W. Stone,
Mark Midei,
William Newman,
Mark Sanz,
James Hermiller,
Jerome Williams,
Naim Farhat,
Ronald Caputo,
Nicholas Xenopoulos,
Robert J. Applegate,
Paul Gordon,
Roseann White,
Krishnankutty Sudhir,
Donald E. Cutlip,
John L. Petersen
Publication year - 2009
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.108.803528
Subject(s) - medicine , myocardial infarction , hazard ratio , stent , everolimus , cardiology , target lesion , coronary artery disease , revascularization , percutaneous coronary intervention , confidence interval
In the prospective randomized Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial, an everolimus-eluting stent (EES) compared with a widely used paclitaxel-eluting stent (PES) resulted in a statistically significant reduction in angiographic in-segment late loss at 8 months and noninferior rates of target vessel failure (cardiac death, myocardial infarction, or target vessel revascularization) at 1 year. The safety and efficacy of EES after 1 year have not been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom